Trial Profile
A Study to Evaluate the Acute Humoral and Cellular Effects during First Alemtuzumab Infusion Week in Active Multiple Sclerosis (MS) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 25 Feb 2016 New trial record